Clinical trial
Efficacy of IV Ibuprofen vs Ketorolac in Controlling Post Operative Pain in Colorectal Cancer Surgeries in Obese Patient: A Randomized Double Blinded Controlled Study
Name
MS-503-2022
Description
The aim of this study is to assess the Efficacy of IV Ibuprofen and Ketorolac in the Management of Postoperative Pain in obese patients Following abdominal cancer surgery.
Trial arms
Trial start
2023-04-01
Estimated PCD
2023-11-15
Trial end
2023-11-15
Status
Completed
Treatment
IV ibuprofen
Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
Arms:
group (I)
IV ketorolac
Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
Arms:
group (II)
Size
50
Primary endpoint
Assessment of Pain
During procedure
Eligibility criteria
Inclusion Criteria:
* ASA class II.
* Age ≥ 18 and ≤ 65 Years.
* Patients undergoing midline abdominal incision for colorectal cancer surgery.
* Body mass index (BMI) \>30 kg/m2.
Exclusion Criteria:
* Renal and hepatic insufficiency.
* Unstable cardiovascular disease.
* History of psychiatric and cognitive disorders.
* Patients allergic to medication used.
* Asthmatic patients.
* Peptic ulcer patients.
* patients on regular opioid consumption.
* History of allergy or hypersensitivity to any component of ibuprofen, other NSAIDs, opioids or COX- 2 inhibitors.
* Subjects with active significant anemia, history of asthma .
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 50, 'type': 'ACTUAL'}}
Updated at
2024-01-19
1 organization
2 products
3 indications
Organization
Cairo UniversityProduct
IBUPROFENIndication
IbuprofenIndication
KetorolacIndication
Colorectal CancerProduct
IV Ketorolac